

Prediction of atrial fibrillation development and progression: Current perspectives

Konstantinos Vlachos, Konstantinos P Letsas, Panagiotis Korantzopoulos, Tong Liu, Stamatis Georgopoulos, Athanasios Bakalakos, Nikolaos Karamichalakis, Sotirios Xydonas, Michael Efremidis, Antonios Sideris

Konstantinos Vlachos, Konstantinos P Letsas, Stamatis Georgopoulos, Athanasios Bakalakos, Nikolaos Karamichalakis, Sotirios Xydonas, Michael Efremidis, Antonios Sideris, Second Department of Cardiology, Laboratory of Cardiac Electrophysiology, "Evangelismos" General Hospital of Athens, 10676 Athens, Greece

Panagiotis Korantzopoulos, First Department of Cardiology, University Hospital of Ioannina, 45110 Ioannina, Greece

Tong Liu, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

Author contributions: Vlachos K and Georgopoulos S wrote the paper; Vlachos K and Xydonas S performed research; Letsas KP, Korantzopoulos P, Liu T, Bakalakos A, Karamichalakis N, Efremidis M and Sideris A designed research, and performed research; all authors read and approved the final version of the manuscript.

Conflict-of-interest statement: None to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Correspondence to: Konstantinos P Letsas, MD, FESC, Second Department of Cardiology, Laboratory of Cardiac Electrophysiology, "Evangelismos" General Hospital of Athens, 45-47 Ipsilantou Street, 10676 Athens, Greece. k.letsas@gmail.com
Telephone: +30-210-7201466
Fax: +30-213-2041344

Received: June 4, 2015

Peer-review started: June 4, 2015

First decision: August 6, 2015

Revised: December 16, 2015

Accepted: January 5, 2016

Article in press: January 7, 2016

Published online: March 26, 2016

Abstract

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Several conventional and novel predictors of AF development and progression (from paroxysmal to persistent and permanent types) have been reported. The most important predictor of AF progression is possibly the arrhythmia itself. The electrical, mechanical and structural remodeling determines the perpetuation of AF and the progression from paroxysmal to persistent and permanent forms. Common clinical scores such as the hypertension, age ≥ 75 years, transient ischemic attack or stroke, chronic obstructive pulmonary disease, and heart failure and the congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category scores as well as biomarkers related to inflammation may also add important information on this topic. There is now increasing evidence that even in patients with so-called lone or idiopathic AF, the arrhythmia is the manifestation of a structural atrial disease which has recently been defined and described as fibrotic atrial cardiomyopathy. Fibrosis results from a broad range of factors related to AF inducing pathologies such as cell stretch, neurohumoral activation, and oxidative stress. The extent of fibrosis as detected either by late gadolinium enhancement-magnetic resonance imaging or electroanatomic voltage mapping may guide the therapeutic approach based on the arrhythmia substrate. The knowledge of these risk factors may not only delay arrhythmia progression, but also reduce the arrhythmia burden in patients with first detected AF. The present review highlights on the conventional and novel risk

factors of development and progression of AF.

Key words: Atrial fibrillation; Development; Progression; Risk factors; Inflammation; Fibrosis

© **The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Atrial fibrillation (AF) is a progressive disease associated with increased morbidity and mortality. Prevention of arrhythmia progression is therefore of paramount importance. An intense rhythm control strategy will prevent structural and electrical remodeling. The modification of common risk factors of AF development and progression such as hypertension, obesity, and sleep apnoea should be additionally considered. Emerging risk factors such as inflammation and fibrosis will guide the therapeutic approach in the future.

Vlachos K, Letsas KP, Korantzopoulos P, Liu T, Georgopoulos S, Bakalagos A, Karamichalakis N, Xydonas S, Efremidis M, Sideris A. Prediction of atrial fibrillation development and progression: Current perspectives. *World J Cardiol* 2016; 8(3): 267-276 Available from: URL: <http://www.wjgnet.com/1949-8462/full/v8/i3/267.htm> DOI: <http://dx.doi.org/10.4330/wjc.v8.i3.267>

INTRODUCTION

Atrial fibrillation (AF) is the most common arrhythmia managed in clinical practice and its incidence increases sharply with age^[1]. AF is associated with increased morbidity and mortality that primarily occur as a result of 2 complications: Stroke and heart failure (HF)^[2]. Mortality is increased because of a combination of altered hemodynamics, atrioventricular dyssynchrony, progressive atrial and ventricular mechanical dysfunction, and thromboembolic complications. The current evidence indicates that the overall prevalence of AF is in the range of 1%-2% of the general population^[3]. Its prevalence is expected to double in the next 50 years as a consequence of prolongation of life^[4]. Significant interest has been directed to risk factors predicting the progression of paroxysmal to permanent AF. The knowledge of these risk factors may not only delay AF progression, but also reduce the arrhythmia burden in patients with first detected AF. The present review highlights on conventional and novel risk factors of development and progression of AF.

DEFINITION OF AF

The American College of Cardiology, the American Heart Association, the Asia Pacific Heart Rhythm Society, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society classified AF as paroxysmal, persistent, longstanding persistent and

permanent AF^[5]. Paroxysmal AF is defined as recurrent AF (2 episodes) that terminates spontaneously within 7 d. Episodes of AF of 48 h duration that are terminated with electrical or pharmacologic cardioversion should also be classified as paroxysmal AF episodes. Persistent AF is defined as continuous AF that is sustained beyond 7 d. Episodes of AF in which a decision is made to electrically or pharmacologically cardiovert the patient after 48 h of AF, but prior to 7 d, should also be classified as persistent AF episodes. Longstanding persistent AF is defined as continuous AF of greater than 12 mo duration. The term permanent AF is not appropriate in the context of patients undergoing catheter or surgical ablation of AF, as it refers to a group of patients for which a decision has been made not to restore or maintain sinus rhythm by any means, including catheter or surgical ablation. If a patient previously classified as having permanent AF is to undergo catheter or surgical ablation, the AF should be reclassified.

CONVENTIONAL AND NOVEL RISK FACTORS OF AF DEVELOPMENT AND PROGRESSION

The development and progression from paroxysmal to persistent and longstanding persistent AF has many risk factors^[6]. Several conventional and novel risk factors have been proposed (Table 1).

AF begets AF

The most important predictor of AF progression is possibly AF itself^[7]. At an early stage, AF determines an atrial electrophysiological, mechanical and structural atrial remodeling by shortening, mismatching and lengthening the atrial effective refractory periods (increase of dispersion) and by the depression of intra-atrial conduction and the loss of contractile function. The electrical, mechanical and structural remodeling determines the perpetuation of AF and the progression from paroxysmal to persistent and permanent forms. The longer one waits to initiate a rhythm treatment strategy, the more difficult it is to regain sinus rhythm. Dittrich *et al*^[8] showed that patients who converted to sinus rhythm within 3 mo of onset of AF were more likely to maintain sinus rhythm at 6 mo than patients who converted more than 12 mo after onset of AF (67% vs 27%). By shortening the atrial refractory period, reducing conduction velocity and provoking contractile and structural remodeling, AF provokes AF^[9].

Valvular heart disease

Almost any valvular lesion that leads to significant stenosis or regurgitation is associated with the development of AF. In patients with degenerative mitral regurgitation in sinus rhythm at diagnosis, the incidence of AF occurring under conservative management is high and similar whether the cause of mitral regurgitation is flail leaflet or simple mitral valve prolapse. After onset of AF,

Table 1 Conventional and novel risk factors for atrial fibrillation development and progression

Well-established risk factors
AF (AF begets AF)
Valvular heart disease
Hypertension
Coronary artery disease
Heart failure
Left atrial dilatation
Diabetes mellitus
Advancing age
Sex (male)
Congenital heart disease
Acute pericarditis
Hyperthyroidism
Alcohol consumption
Less-established risk factors
Obstructive pulmonary disease
Obstructive sleep apnea syndrome
Obesity
Left ventricular diastolic dysfunction
Atrial conduction delay (PR interval prolongation)
Genetic factors
Ethnicity
Emerging risk factors
Chronic kidney disease
Fibrosis
Inflammation
Elevated natriuretic peptides

AF: Atrial fibrillation.

an increased cardiac mortality and morbidity are both observed under conservative management^[10]. Rheumatic heart disease is now uncommon in developed countries. It is, however, associated with high prevalence of AF. The highest frequency of AF in rheumatic heart disease occurs in those with mitral stenosis, mitral regurgitation, and tricuspid regurgitation in combination. AF, while occurring in 29% of patients with isolated mitral stenosis and in 16% with isolated mitral regurgitation, is an infrequent finding (1%) in patients with aortic valvular disease^[11]. In addition, John *et al.*^[12] compared patients with mitral stenosis with 24 control patients. Patients with mitral stenosis showed, not only left atrial enlargement, but also a significantly reduced biatrial voltage (left atrium 1.8 + 0.6 mV vs 3.6 + 0.6 mV, right atrium 1.9 + 0.6 mV vs 3.3 + 0.5 mV), reduced conduction velocity, and prolonged effective refractory periods. These abnormalities may clearly play a role in the increased propensity to AF in patients with mitral stenosis.

Hypertensive heart disease

The association between hypertension and AF is well established. A history of hypertension increases 1.42-fold the risk of developing AF^[13]. Although the increase in risk is relatively modest (relative risk, 1.2-1.5), the high prevalence of hypertension in the general population renders it the most significant population-attributable risk factor for AF beyond age and sex. It is observed that hypertension is responsible for 14% of all cases of AF^[14]. Although overt systolic hypertension is strongly related with the progression of AF, recent studies demonstrated

that systolic blood pressure in the prehypertensive range (130-139 mmHg) and widened pulse pressure are also associated with increased incidence of AF^[15,16]. Mean arterial pressure does not seem to be related with AF.

Coronary artery disease

AF occurs transiently in 6%-10% of patients with acute myocardial infarction, presumably due to atrial ischemia or atrial stretching secondary to HF^[17]. These patients have a worse prognosis that is mostly due to comorbidities such as older age and HF. The Coronary Artery Surgical study which included 18000 patients showed that the incidence of AF is much lower (0.6%) in patients with chronic stable coronary artery disease (CAD)^[16]. These patients probably had chronic AF; the prevalence of paroxysmal AF may be higher. AF was an independent predictor of increased mortality in patients with stable CAD^[18]. Coronary artery disease can promote AF *via* multiple mechanisms. Myocardial infarction often causes substantial left ventricular dysfunction and HF predisposing to AF. Acute atrial ischemia/injury promotes AF by causing important atrial conduction disturbances, likely related to impaired cell-to-cell coupling^[19]. Healed atrial infarctions and persistent ischemia enhances AF by causing Ca²⁺ - handling abnormalities, resulting in delayed afterdepolarizations and triggered activity resulting in ectopic firing, along with structural remodeling and reentry^[20]. Chronic atrial coronary artery occlusion in conjunction with autonomic activity promotes ectopic firing and AF.

Age and sex

Aging is accompanied by atrial structural remodeling associated with substantial conduction abnormalities^[21]. Gaborit *et al.*^[22] showed that men have greater expression of important repolarizing ion channel subunits, which could enhance atrial repolarization, shorten atrial refractoriness, and favor reentry. Moreover, men have greater left atrial dimensions that could promote AF maintenance^[23].

Diabetes mellitus

Diabetes mellitus is an independent determinant of AF prevalence but predicted incidence only among women^[24]. Over a mean follow-up of 7.2 years, diabetic patients without AF at baseline developed AF at an age/sex-adjusted rate of 9.1/1000 person-years, compared with 6.6/1000 person years among non-diabetic patients. Diabetes mellitus was associated with 26% increased risk of AF among women, but diabetes was not a statistically significant factor among men. Diabetes mellitus elicits AF *via* both structural remodeling, mediated by advanced glycosylation end products^[25] and autonomic nervous system remodeling^[26].

HF

AF and HF often occur together and each may predispose to the other. There is continuing controversy as to whether HF is merely a common coexisting condition among patients with AF or whether it is a true causative

factor. Among patients with HF, the prevalence of AF is variable, depending in part upon the severity of HF. The association is not limited to systolic left ventricular dysfunction but also AF is combined with diastolic dysfunction of the left ventricle^[27]. Isolated diastolic dysfunction is associated with an increased AF incidence, possibly reflecting shared risk factors such as advancing age and hypertension. Although the association between AF and HF is well established, the causative relationship between the two has not been fully elucidated. Probably, AF can cause reductions in cardiac output (because of shorter diastolic filling time, loss of atrial contractile function, and elevated filling pressures) and tachycardia-induced cardiomyopathy^[28]. HF results in structural and electrical remodeling changes that predispose to AF.

Hypertrophic cardiomyopathy

AF has been reported in 10%-28% of patients with hypertrophic cardiomyopathy (HCM)^[29]. AF is the most common arrhythmia in patients with HCM. Olivotto *et al*^[30] evaluated 480 patients with HCM with a mean follow-up of 9.1 years and found the prevalence of AF to be 22%. More recently, a study in Japan examined 261 patients with HCM and found that 74 (28%) patients had documented paroxysmal AF or permanent AF^[31]. The high prevalence of AF in HCM is related to atrial dilation and remodeling in the setting of diastolic dysfunction, mitral regurgitation, and atrial fibrosis^[30,31]. AF is an important prognostic indicator in patients with HCM, because these patients are typically at a higher New York Heart Association functional class and have a poorer outcome. This subgroup of patients with HCM is at an increased risk of cardiovascular morbidity and mortality in the form of thromboembolic events, HF, and sudden death^[32]. In a systematic review, Kumar *et al*^[33] reported that in HCM brain natriuretic peptide, left atrial size (left atrial volume measured with cardiac magnetic resonance), higher left atrial mean extent of late gadolinium enhancement in cardiac magnetic resonance, left ventricular myocardial fibrosis determined by delayed contrast enhancement, sleep apnea, longer *P*-wave duration, genetic factors, and ischemia are associated with AF progression.

Dilated cardiomyopathy

AF is common in patients with dilated cardiomyopathy (DCM). Epidemiologic studies have shown that 30%-40% of patients with left ventricular dysfunction and systolic HF from any cause will develop AF during the course of their disease, and AF has been associated with increased morbidity and mortality^[34-36]. In experimental subjects, the increased incident of AF is associated with atrial structural abnormalities, with increased atrial fibrosis associated with slowing conduction of velocity and conduction heterogeneity^[37]. In humans, Sanders *et al*^[38] also showed that AF in patients with left ventricular dysfunction is associated with widespread areas of low voltage and electrical silence consistent with scar, and with regional atrial conduction slowing with prolongation

of the *P*-wave duration, in addition to altered sinus node function. Pulmonary veins are responsible for arrhythmia initiation^[39]. Atrial electrical and structural remodeling outside the pulmonary veins is the substrate of maintenance of persistent AF. Rotors, or high-frequency sources within the atrium, have been recently proposed as mechanisms for both initiation and maintenance of persistent AF^[40].

Peripartum cardiomyopathy

In 2007, the European Society of Cardiology working group on myocardial and pericardial diseases redefined cardiomyopathies including peripartum cardiomyopathy (PPCM), which it is defined as a form of DCM that presents with signs of cardiac failure during the last month of pregnancy or within 5 mo of delivery^[41]. Limited data regarding the association of PPCM and AF exist in the literature. Biteker *et al*^[42] studied 42 women with PPCM. Five of them (11.9%) had AF and AF had no apparent effect on survival or recovery of left ventricular function. Kane *et al*^[43] examined 33 women with PPCM and 1 (3%) of them had AF. Finally, Isezuo and Abubakar^[44] showed that 2 out of 65 women (3.1%) developed AF strengthening the observation that PPCM is associated with AF.

Chronic kidney disease

AF is more prevalent in patients with chronic renal dysfunction (CRD). AF risk increases with severity of kidney dysfunction (HR of 1.3-1.6 and 1.6-3.2 with an estimated glomerular filtration rate of 30-59 and < 30 mL/min per 1.73 m², respectively, vs estimated glomerular filtration rate \geq 60 mL/min per 1.73 m²)^[45]. These two entities (AF and CRD) share common associated factors such as coronary heart disease, HF, hypertension, left ventricular hypertrophy and systemic inflammation. In addition, macroalbuminuria and microalbuminuria were significantly associated with higher AF risk.

Sleep apnea and obesity

Accumulating data have demonstrated a clear and significant association between obstructive sleep apnea (OSA) and AF^[46,47]. The occurrence of AF in 400 middle-aged patients who had moderate or severe OSA (apnea-hypopnea index \geq 25) was more than 3%. Furthermore, twelve of the study patients who underwent tracheostomy, bypassing the obstructed airway, had complete elimination of AF up to 6 mo later, something that clearly shows the straight correlation between AF and OSA^[46]. In the largest registry until now, Gami *et al*^[47] showed that OSA and AF were significantly associated. Body mass index and the decrease in nocturnal oxygen saturation were independent predictors of AF. This study, also, proves the correlation between obesity and AF. Multiple pathophysiological pathways link OSA with AF. Increased left atrial size, hypertension and diastolic dysfunction may coexist in OSA and AF^[48]. AF probably occurs as a complex interaction of several hemodynamic and sympathetic consequences of OSA.

These include autonomic dysregulation^[49], elevated sympathetic tone, oxidative stresses, endothelial dysfunction, and left atrial stretch^[50]. OSA is associated with systemic inflammation, increased levels of C-reactive protein (CRP), serum amyloid A, and interleukins^[51]. These observations makes us believe that OSA and AF share common pathways, which contribute to atrial fibrosis and structural and electrical remodeling. Finally, Al Chekakie *et al.*^[52] showed that central obesity and pericardial fat is associated with AF. Pericardial adipose tissue contributes to inflammation and progression to AF. Patients with paroxysmal AF had significantly greater pericardial fat volume on average than patients in sinus rhythm (93.9 mL vs 76.1 mL) and the persistent AF patients had a significantly larger volume of pericardial fat volume on average than the paroxysmal AF patients (115.4 mL vs 93.9 mL).

Congenital heart disease

AF has been reported in approximately 20% of adults with an arial septal defect^[53]. AF and atrial flutter also occurs in other forms of congenital heart disease that affect the atria, including Ebstein's anomaly^[54] and patent ductus arteriosus^[55], and after surgical correction of some other abnormalities, including ventricular septal defect, tetralogy of Fallot, pulmonary valve stenosis, and transposition of the great vessels.

Hyperthyroidism

Patients with hyperthyroidism have an increased risk of AF progression^[56]. Frost *et al.*^[57] showed that among 40628 patients with clinical hyperthyroidism, 8.3% had AF or atrial flutter. Increased beta adrenergic tone play a crucial role for the development of AF in hyperthyroidism, often combined with rapid ventricular response. Furthermore, hyperthyroidism increases the likelihood of AF in experimental models, even in the presence of beta receptor and vagal blockade^[58]. The pathophysiology remains unknown, but may be related to an increased automaticity and enhanced triggered activity of pulmonary vein cardiomyocytes^[59]. The risk for development of AF is also increased in patients with subclinical hyperthyroidism^[60,61]. It remains controversial whether patients with AF associated with previous treated thyrotoxicosis are at increased risk of thromboembolism, in the absence of other known risk factors^[62].

Other clinical risk factors

AF is associated with a variety of other types of cardio-pulmonary disease. AF is seen in 10% to 14% of patients with documented pulmonary embolism^[63]. AF also occurs in chronic obstructive pulmonary disease^[64], myocarditis^[65] and acute pericarditis^[66]. In addition, electrolytic disturbances like hypokalemia or low serum magnesium^[67] initiates AF. Alcohol consumption contributes, also, to the development of AF^[68]. Finally, prior surgery, especially and coronary artery bypass grafting^[69] predispose to AF.

CLINICAL RISK SCORES FOR PREDICTION OF AF DEVELOPMENT AND PROGRESSION

The HATCH score [hypertension - age (75 years and older) - transient ischemic attack or stroke (2 points) - chronic obstructive pulmonary disease - HF (2 points)] allows an instant classification of the risk of progression to persistent or permanent AF in patients with paroxysmal AF^[70]. de Vos *et al.*^[70] showed that nearly 50% of the patients with a HATCH score more than 5 progressed persistent AF, compared with only 6% of the patients with a HATCH score of 0. Malik *et al.*^[71] described LADS score [left atrial diameter (0-2 points), age (0-2 points), diagnosis of stroke (0-1 point), and smoking status currently (0-1 point)], a 6-point scoring system. A score of 4 or greater was associated with a sensitivity of 85.5% and a specificity of 53.1% for progression AF. CHADS2 score [one point each for age > 75 years, hypertension, diabetes and HF or low ejection fraction, and two points for history of prior stroke or transient ischemic attack (TIA)] and CHA2DS2-VASc score [congestive HF (1 point), hypertension (1 point), diabetes mellitus (1 point), history of stroke, TIA or thromboembolism (2 points), vascular disease (history of myocardial infarction, peripheral vascular disease or aortic atherosclerosis) (1 point), age 65-74 years old (1 point), age > 75 years old (2 points), sex male (0 points), female (1 point)] has been shown to be associated with post-ablation AF recurrences^[5]. Letsas *et al.*^[72] examined 126 patients with symptomatic paroxysmal AF who underwent left atrial ablation. Over 16 mo, 89 patients were recurrence-free (70.6%). In the multivariate analysis, both CHADS2 and CHA2DS2-VASc score were independently associated with AF recurrence. Cut-off analysis showed that a score ≥ 2 for both CHADS2 and CHA2DS2-VASc scores showed the highest predictive value for AF recurrence.

BIOMARKERS FOR PREDICTION OF AF DEVELOPMENT AND PROGRESSION

Several biomarkers have been proposed as predictors of occurrence and progression of AF. Bruins *et al.*^[73] were the first to propose a direct link between inflammation and AF by observing an increased frequency of AF after coronary artery bypass surgery, where AF occurred on the second and third postoperative day coinciding with the peak elevation of CRP. CRP is an acute phase protein, which is directly related to inflammation. Raised levels of CRP have been noted to be higher among patients with AF when compared with patients in sinus rhythm^[74]. Persistent AF patients have a higher CRP than paroxysmal AF patients, and both groups have a higher CRP than controls. Furthermore, CRP is considered as a significant predictor of early AF relapse after successful cardioversion, even after adjustment for multiple risk factors, such as hypertension and coronary artery disease^[75]. Microalbuminuria combined with an elevated

CRP raises fourfold the risk of AF^[76]. Korantzopoulos *et al*^[77] presented data from a study of 30 AF patients undergoing cardioversion. Patients with arrhythmia relapse exhibited an increase in fibrinogen levels compared with those who remained in sinus rhythm. In addition, there was a trend to reduced CRP levels among those patients who were successfully cardioverted compared with those who relapsed. IL-6 plays a key role in inflammation and to the progression of AF. Gaudino *et al*^[78] showed that a 174G/C polymorphism of the promoter of the *IL-6* gene appears to influence the development of postoperative AF supporting the role of inflammation in the development of postoperative AF. The importance of troponin, as a biomarker, in an AF population was first described in a substudy of RELY trial^[79]. The results indicated that troponin I levels ≥ 0.01 mg/L were seen in 55% of the 6189 patients with AF and at least one risk factor for stroke. Troponin was significantly and independently associated with increased risk of stroke, systemic embolism and cardiovascular death. These results were in concordance with the ARISTOTLE biomarker study where 14892 patients with AF were treated either with apixaban or warfarin in order to reduce the risk of stroke^[80]. The ARISTOTLE troponin substudy results proved that the troponin levels were related to the risk of thrombo-embolic events and cardiovascular death. Other biomarkers which are increased in wall tension such as volume or pressure overload and are related with AF is B-type natriuretic peptide (BNP) and N-terminal fragment (NT-proBNP). Ellinor *et al*^[81] first described that patients with AF had elevated levels of natriuretic peptides compared with matched controls in sinus rhythm. The levels of natriuretic peptides fall rapidly following restoration of sinus rhythm^[82]. Patton *et al*^[83] recently reported that elevated NT-proBNP levels predict an increased risk of development of AF independent of other risk factors including echocardiographic parameters. In addition, a substudy of the RELY trial showed that the level of NT-proBNP was associated with the risk of thrombo-embolic events and cardiovascular mortality^[79]. Plasma D-dimer is a marker of fibrin turnover, and is used as an index of thrombogenesis. A substudy of the ARISTOTLE trial showed that D-dimer levels were a predictor of stroke, mortality and major bleeding^[84].

IMAGING FOR PREDICTION OF AF DEVELOPMENT AND PROGRESSION

Echocardiographic parameters

Left atrial size is a well-known predictor of AF development. A left atrial size greater than 4 cm has been associated with a significantly higher AF recurrence rate^[85]. The left atrial volume measured by transthoracic echocardiography is possibly superior to left atrial diameter in predicting progression to persistent AF^[86]. Li *et al*^[87] reported that the E/e' index (E, early transmitral flow velocity; e', early diastolic mitral annular velocity), an

index of diastolic dysfunction, was the best independent predictor of AF recurrence after catheter ablation. E/e' > 11.2 before ablation has been associated with AF recurrence. Shaikh *et al*^[88] showed that speckle left atrial strain and stiffness index can predict the possibility of maintenance in sinus rhythm after cardioversion for AF. Changes in longitudinal left atrial strain (peak systolic longitudinal strain) after cardioversion were significantly higher among individuals who remained in sinus rhythm when compared to individuals with recurrent AF^[88].

Magnetic resonance imaging and voltage mapping

Late gadolinium enhancement-magnetic resonance imaging (LGE-MRI) allows the direct visualization of atrial arrhythmic substrate. Vergara *et al*^[89] described a new staging system for AF based on the amount of left atrial enhancement on LGE-MRI, the Utah score (Utah I $\leq 5\%$, Utah II $> 5\%$ -20%, Utah III $> 20\%$ -35%, and Utah IV $> 35\%$). On the basis of patient stage, a more tailored approach to AF management can be taken. Patients with a previous stroke had a significantly higher percentage of left atrial fibrosis compared with those without ($24.4\% \pm 12.4\%$ vs $16.1\% \pm 9.8\%$, $P \leq 0.001$). There was a significant difference in the rate of thromboembolism between patients with stage I and those with stage IV of atrial remodeling as assessed by LGE-MRI. In addition patients with CHADS2 score ≥ 2 had higher amounts of left atrial fibrosis. The DECAAF study showed that left atrial fibrosis contributes to the progression of AF. The more fibrosis there is, the more likely the arrhythmia will persist following ablation^[90]. Atrial fibrosis estimated by LGE-MRI in 260 AF patients, including 65% with paroxysmal AF, was a significant predictor of recurrence. Each 1% increase in fibrosis was associated with a 6% increased risk of recurrence. Fibrosis was categorized as stage 1 ($< 10\%$ of the atrial wall), 2 ($\geq 10\%$ - $< 20\%$), 3 ($\geq 20\%$ - $< 30\%$), and 4 ($\geq 30\%$). At one year, 88% of patients with stage 1 fibrosis were free of AF. For those with stage 2, 3, or 4 fibrosis, 69%, 55%, and 45% were free of recurrence at one year, respectively. At 475 d, 86%, 64%, 51%, and 35% of those with stage 1, 2, 3, and 4 fibrosis were free of AF, respectively. Electroanatomic bipolar voltage mapping has proved to have great correlation with DE-MRI. Jadidi *et al*^[91] have demonstrated bipolar voltages of 0.63 ± 0.8 in dense DE-CMRI areas, compared with 0.86 ± 0.89 in non DE-MRI areas. Moreover, Spragg *et al*^[92] have demonstrated that the mean atrial voltage in areas identified as scar by DE-MRI was 0.39 ± 0.61 mV, while in areas identified as normal by DE-CMRI was 1.38 ± 1.23 mV.

There is now increasing evidence that even in patients with so-called lone or idiopathic AF, the AF is an arrhythmic manifestation of a structural atrial disease which has recently been defined and described as fibrotic atrial cardiomyopathy (FACM). Different expressions can be found from mild (FACM I), moderate (FACM II) to excessive fibrosis (FACM III), and wide clinical variations from asymptomatic to multiple arrhythmic

manifestations (including AF, left and/or right atrial re-entrant tachycardia, sinus, and/or atrioventricular node disease)^[93]. Fibrosis results from a broad range of factors related to AF inducing pathologies such as cell stretch, neurohumoral activation, oxidative stress, and possibly even AF itself^[94]. Stiles *et al.*^[95] investigated 25 patients with "lone" AF, during an electrophysiological study after at least 7 d in sinus rhythm, and found slower conduction velocity, longer effective refractory periods, and significantly lower voltages (left atrium 1.7 + 0.7 mV vs 3.3 + 0.7 mV, right atrium 1.7 + 0.4 mV vs 2.9 + 0.4 mV) compared with control patients without AF. These findings confirm a substantial chronic structural atrial substrate since the electrical remodelling is reversible within a few days. It might be that not all patients with paroxysmal "lone" AF have an underdetected chronic substrate, but many more than assumed. The debate is whether the fibrosis is causative or merely a result of AF. Several data suggest that fibrosis is causative and that AF-induced fibrosis may be part of the vicious cycle. In animal models, reversal or prevention of fibrosis prevents AF^[96]. Furthermore, AF substrate in the absence of any cellular electrophysiological abnormalities has been demonstrated in a transgenic mouse model of isolated atrial fibrosis^[97].

CONCLUSION

AF is a progressive disease associated with increased morbidity and mortality. Prevention of arrhythmia progression is therefore of paramount importance. An intense rhythm control strategy may be the first step towards this direction (sinus rhythm begets sinus rhythm). The modification of common risk factors of AF development and progression such as hypertension, obesity, and sleep apnoea should be additionally considered. Emerging risk factors such as inflammation and fibrosis will guide the therapeutic approach of AF in the future.

REFERENCES

- 1 **Lip GY**, Tse HF, Lane DA. Atrial fibrillation. *Lancet* 2012; **379**: 648-661 [PMID: 22166900 DOI: 10.1016/S0140-6736(11)61514-6]
- 2 **Kannel WB**, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. *N Engl J Med* 1982; **306**: 1018-1022 [PMID: 7062992 DOI: 10.1056/NEJM198204293061703]
- 3 **Piccini JP**, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, Benjamin EJ, Curtis LH. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. *Circ Cardiovasc Qual Outcomes* 2012; **5**: 85-93 [PMID: 22235070 DOI: 10.1161/CIRCOUTCOMES.111.962688]
- 4 **Disertori M**, Lombardi F, Barlera S, Maggioni AP, Favero C, Franzosi MG, Lucci D, Staszewsky L, Fabbri G, Quintarelli S, Bianconi L, Latini R. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. *Am Heart J* 2011; **162**: 382-389 [PMID: 21835301 DOI: 10.1016/j.ahj.2011.05.008]
- 5 **Calkins H**, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D; Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. *Heart Rhythm* 2012; **9**: 632-696.e21 [PMID: 22386883 DOI: 10.1016/j.hrthm.2011.12.016]
- 6 **Wyse DG**, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM, Nattel S, Schotten U, Rienstra M. Lone atrial fibrillation: does it exist? *J Am Coll Cardiol* 2014; **63**: 1715-1723 [PMID: 24530673 DOI: 10.1016/j.jacc.2014.01.023]
- 7 **Lu Z**, Scherlag BJ, Lin J, Niu G, Fung KM, Zhao L, Ghias M, Jackman WM, Lazzara R, Jiang H, Po SS. Atrial fibrillation begets atrial fibrillation: autonomic mechanism for atrial electrical remodeling induced by short-term rapid atrial pacing. *Circ Arrhythm Electrophysiol* 2008; **1**: 184-192 [PMID: 19808412 DOI: 10.1161/CIRCEP.108.784272]
- 8 **Dittrich HC**, Erickson JS, Schneiderman T, Blacky AR, Savides T, Nicod PH. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. *Am J Cardiol* 1989; **63**: 193-197 [PMID: 2909999 DOI: 10.1016/0002-9149(89)90284-1]
- 9 **Van Gelder IC**, Hemels ME. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. *Europace* 2006; **8**: 943-949 [PMID: 16973685 DOI: 10.1093/europace/eul107]
- 10 **Grigioni F**, Avierinos JF, Ling LH, Scott CG, Bailey KR, Tajik AJ, Frye RL, Enriquez-Sarano M. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. *J Am Coll Cardiol* 2002; **40**: 84-92 [PMID: 12103260 DOI: 10.1016/S0735-1097(02)01922-8]
- 11 **Diker E**, Aydogdu S, Ozdemir M, Kural T, Polat K, Cehreli S, Erdogan A, Göksel S. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. *Am J Cardiol* 1996; **77**: 96-98 [PMID: 8540469 DOI: 10.1016/S0002-9149(97)89145-X]
- 12 **John B**, Stiles MK, Kuklik P, Chandy ST, Young GD, Mackenzie L, Szumowski L, Joseph G, Jose J, Worthley SG, Kalman JM, Sanders P. Electrical remodelling of the left and right atria due to rheumatic mitral stenosis. *Eur Heart J* 2008; **29**: 2234-2243 [PMID: 18621772 DOI: 10.1093/eurheartj/ehn329]
- 13 **Krahn AD**, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med* 1995; **98**: 476-484 [PMID: 7733127 DOI: 10.1016/S0002-9343(99)80348-9]
- 14 **Kannel WB**, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol* 1998; **82**: 2N-9N [PMID: 9809895]
- 15 **Conen D**, Tedrow UB, Koplán BA, Glynn RJ, Buring JE, Albert

- CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. *Circulation* 2009; **119**: 2146-2152 [PMID: 19364977 DOI: 10.1161/CIRCULATIONAHA.108.830042]
- 16 **Mitchell GF**, Vasani RS, Keyes MJ, Parise H, Wang TJ, Larson MG, D'Agostino RB, Kannel WB, Levy D, Benjamin EJ. Pulse pressure and risk of new-onset atrial fibrillation. *JAMA* 2007; **297**: 709-715 [PMID: 17312290 DOI: 10.1001/jama.297.7.709]
- 17 **Crenshaw BS**, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. *J Am Coll Cardiol* 1997; **30**: 406-413 [PMID: 9247512 DOI: 10.1016/S0735-1097(97)00194-0]
- 18 **Cameron A**, Schwartz MJ, Kronmal RA, Kosinski AS. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). *Am J Cardiol* 1988; **61**: 714-717 [PMID: 3258467 DOI: 10.1016/0002-9149(88)91053-3]
- 19 **Sinno H**, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. *Circulation* 2003; **107**: 1930-1936 [PMID: 12668526 DOI: 10.1161/01.CIR.000058743.15215.03]
- 20 **Nishida K**, Qi XY, Wakili R, Comtois P, Chartier D, Harada M, Iwasaki YK, Romeo P, Maguy A, Dobrev D, Michael G, Talajic M, Nattel S. Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model. *Circulation* 2011; **123**: 137-146 [PMID: 21200008 DOI: 10.1161/CIRCULATIONAHA.110.972778]
- 21 **Wakili R**, Voigt N, Kääh S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. *J Clin Invest* 2011; **121**: 2955-2968 [PMID: 21804195 DOI: 10.1172/JCI46315]
- 22 **Gaborit N**, Varro A, Le Bouter S, Szuts V, Escande D, Nattel S, Demolombe S. Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. *J Mol Cell Cardiol* 2010; **49**: 639-646 [PMID: 20600101 DOI: 10.1016/j.yjmcc.2010.06.005]
- 23 **Liu XK**, Jahangir A, Terzic A, Gersh BJ, Hammill SC, Shen WK. Age- and sex-related atrial electrophysiologic and structural changes. *Am J Cardiol* 2004; **94**: 373-375 [PMID: 15276110 DOI: 10.1016/j.amjcard.2004.04.040]
- 24 **Nichols GA**, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. *Diabetes Care* 2009; **32**: 1851-1856 [PMID: 19794003 DOI: 10.2337/dc09-0939]
- 25 **Kato T**, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M, Kaneko S, Aizawa T, Fu LT. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. *J Cardiovasc Electrophysiol* 2008; **19**: 415-420 [PMID: 18298515 DOI: 10.1111/j.1540-8167.2007.01037.x]
- 26 **Otake H**, Suzuki H, Honda T, Maruyama Y. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. *Int Heart J* 2009; **50**: 627-641 [PMID: 19809211 DOI: 10.1536/ihj.50.627]
- 27 **Tsang TS**, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. *J Am Coll Cardiol* 2002; **40**: 1636-1644 [PMID: 12427417 DOI: 10.1016/S0735-1097(02)02373-2]
- 28 **Houmsse M**, Tyler J, Kalbfleisch S. Supraventricular tachycardia causing heart failure. *Curr Opin Cardiol* 2011; **26**: 261-269 [PMID: 21460716 DOI: 10.1097/HCO.0b013e328345b010]
- 29 **Cecchi F**, Olivetto I, Monterecci A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. *J Am Coll Cardiol* 1995; **26**: 1529-1536 [PMID: 7594081 DOI: 10.1016/0735-1097(95)00353-3]
- 30 **Olivetto I**, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation* 2001; **104**: 2517-2524 [PMID: 11714644 DOI: 10.1161/hc4601.097997]
- 31 **Kubo T**, Kitaoka H, Okawa M, Hirota T, Hoshikawa E, Hayato K, Yamasaki N, Matsumura Y, Yabe T, Nishinaga M, Takata J, Doi YL. Clinical profiles of hypertrophic cardiomyopathy with apical phenotype--comparison of pure-apical form and distal-dominant form. *Circ J* 2009; **73**: 2330-2336 [PMID: 19838003 DOI: 10.1253/circj.CJ-09-0438]
- 32 **Doi Y**, Kitaoka H. Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation. *J Cardiol* 2001; **37** Suppl 1: 133-138 [PMID: 11433817]
- 33 **Kumar KR**, Mandleywala SN, Link MS. Atrial and ventricular arrhythmias in hypertrophic cardiomyopathy. *Card Electrophysiol Clin* 2015; **7**: 173-186 [PMID: 26002384 DOI: 10.1016/j.ccep.2015.03.002]
- 34 **Stevenson WG**, Stevenson LW. Atrial fibrillation in heart failure. *N Engl J Med* 1999; **341**: 910-911 [PMID: 10486424 DOI: 10.1056/NEJM199909163411209]
- 35 **Middlekauff HR**, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. *Circulation* 1991; **84**: 40-48 [PMID: 2060110 DOI: 10.1161/01.CIR.84.1.40]
- 36 **Wang TJ**, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasani RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. *Circulation* 2003; **108**: 977-982 [PMID: 12912813 DOI: 10.1161/01.CIR.0000085166.44904.79]
- 37 **Roy D**, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med* 2008; **358**: 2667-2677 [PMID: 18565859 DOI: 10.1056/NEJMoa0708789]
- 38 **Sanders P**, Morton JB, Davidson NC, Spence SJ, Vohra JK, Sparks PB, Kalman JM. Electrical remodeling of the atria in congestive heart failure: electrophysiologic and electroanatomic mapping in humans. *Circulation* 2003; **108**: 1461-1468 [PMID: 12952837 DOI: 10.1161/01.CIR.0000090688.49283.67]
- 39 **Haïssaguerre M**, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998; **339**: 659-666 [PMID: 9725923 DOI: 10.1056/NEJM199809033391003]
- 40 **Narayan SM**, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. *J Am Coll Cardiol* 2012; **60**: 628-636 [PMID: 22818076 DOI: 10.1016/j.jacc.2012.05.022]
- 41 **Elliott P**, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2008; **29**: 270-276 [PMID: 17916581 DOI: 10.1093/eurheartj/ehm342]
- 42 **Biteker M**, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. *Eur J Heart Fail* 2012; **14**: 895-901 [PMID: 22588321 DOI: 10.1093/eurjhf/hfs070]
- 43 **Kane A**, Mbaye M, Ndiaye MB, Diao M, Moreira PM, Mboup C, Diop IB, Sarr M, Kane A, Moreau JC, Ba SA. [Evolution and thromboembolic complications of the idiopathic peripartum cardiomyopathy at Dakar University Hospital: forward-looking study about 33 cases]. *J Gynecol Obstet Biol Reprod (Paris)* 2010; **39**: 484-489 [PMID: 20472372 DOI: 10.1016/j.jgyn.2010.01.008]
- 44 **Isezu SA**, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. *Ethn Dis* 2007; **17**: 228-233 [PMID: 17682350]

- 45 **Watanabe H**, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. *Am Heart J* 2009; **158**: 629-636 [PMID: 19781424 DOI: 10.1016/j.ahj.2009.06.031]
- 46 **Guilleminault C**, Conolly SJ, Winkle RA: Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. *Am J Cardiol* 1983; **52**: 490-494 [PMID: 6193700 DOI: 10.1016/0002-9149(83)90013-9]
- 47 **Gami AS**, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. *J Am Coll Cardiol* 2007; **49**: 565-571 [PMID: 17276180 DOI: 10.1016/j.jacc.2006.08.060]
- 48 **Chobanian AV**, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; **289**: 2560-2572 [PMID: 12748199 DOI: 10.1001/jama.289.19.2560]
- 49 **Somers VK**, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. *J Clin Invest* 1995; **96**: 1897-1904 [PMID: 7560081 DOI: 10.1172/JCI118235]
- 50 **Virolainen J**, Ventilä M, Turto H, Kupari M. Effect of negative intrathoracic pressure on left ventricular pressure dynamics and relaxation. *J Appl Physiol* (1985) 1995; **79**: 455-460 [PMID: 7592202]
- 51 **Liu T**, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. *J Am Coll Cardiol* 2007; **49**: 1642-1648 [PMID: 17433956 DOI: 10.1016/j.jacc.2006.12.042]
- 52 **Al Chekatie MO**, Welles CC, Metoyer R, Ibrahim A, Shapira AR, Cytron J, Santucci P, Wilber DJ, Akar JG. Pericardial fat is independently associated with human atrial fibrillation. *J Am Coll Cardiol* 2010; **56**: 784-788 [PMID: 20797492 DOI: 10.1016/j.jacc.2010.03.071]
- 53 **Tikoff G**, Schmidt AM, Hecht HH. Atrial fibrillation in atrial septal defect. *Arch Intern Med* 1968; **121**: 402-405 [PMID: 5645716 DOI: 10.1001/archinte.1968.03640050012003]
- 54 **Stulak JM**, Sharma V, Cannon BC, Ammash N, Schaff HV, Dearani JA. Optimal surgical ablation of atrial tachyarrhythmias during correction of Ebstein anomaly. *Ann Thorac Surg* 2015; **99**: 1700-1705; discussion 1705 [PMID: 25825196 DOI: 10.1016/j.athoracsur.2015.01.037]
- 55 **Lai YQ**, Li JH, Li JW, Xu SD, Luo Y, Zhang ZG. Concomitant irrigated monopolar radiofrequency ablation of atrial fibrillation in adults with congenital heart disease. *Interact Cardiovasc Thorac Surg* 2008; **7**: 80-82 [PMID: 18024493 DOI: 10.1510/ievt.2007.165225]
- 56 **Woebler KA**. Thyrotoxicosis and the heart. *N Engl J Med* 1992; **327**: 94-98 [PMID: 1603141 DOI: 10.1056/NEJM199207093270206]
- 57 **Frost L**, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. *Arch Intern Med* 2004; **164**: 1675-1678 [PMID: 15302638 DOI: 10.1001/archinte.164.15.1675]
- 58 **Arnsdorf MF**, Childers RW. Atrial electrophysiology in experimental hyperthyroidism in rabbits. *Circ Res* 1970; **26**: 575-581 [PMID: 4191904 DOI: 10.1161/01.RES.26.5.575]
- 59 **Chen YC**, Chen SA, Chen YJ, Chang MS, Chan P, Lin CI. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. *J Am Coll Cardiol* 2002; **39**: 366-372 [PMID: 11788233 DOI: 10.1016/S0735-1097(01)01731-4]
- 60 **Sawin CT**, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* 1994; **331**: 1249-1252 [PMID: 7935681 DOI: 10.1056/NEJM199411103311901]
- 61 **Auer J**, Scheibner P, Mische T, Langsteiger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. *Am Heart J* 2001; **142**: 838-842 [PMID: 11685172 DOI: 10.1067/mhj.2001.119370]
- 62 **Camm AJ**, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010; **31**: 2369-2429 [PMID: 20802247 DOI: 10.1093/eurheartj/ehq278]
- 63 **Goldhaber SZ**, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet* 1999; **353**: 1386-1389 [PMID: 10227218 DOI: 10.1016/S0140-6736(98)07534-5]
- 64 **Buch P**, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. *Eur Respir J* 2003; **21**: 1012-1016 [PMID: 12797497 DOI: 10.1183/09031936.03.00051502]
- 65 **Morgera T**, Di Lenarda A, Dreas L, Pinamonti B, Humar F, Bussani R, Silvestri F, Chersevani D, Camerini F. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. *Am Heart J* 1992; **124**: 455-467 [PMID: 1636589 DOI: 10.1016/0002-8703(92)90613-Z]
- 66 **Spodick DH**. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. *JAMA* 1976; **235**: 39-41 [PMID: 945999 DOI: 10.1001/jama.1976.03260270025020]
- 67 **Khan AM**, Lubitz SA, Sullivan LM, Sun JX, Levy D, Vasan RS, Magnani JW, Ellinor PT, Benjamin EJ, Wang TJ. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. *Circulation* 2013; **127**: 33-38 [PMID: 23172839 DOI: 10.1161/CIRCULATIONAHA.111.082511]
- 68 **Larsson SC**, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. *J Am Coll Cardiol* 2014; **64**: 281-289 [PMID: 25034065 DOI: 10.1016/j.jacc.2014.03.048]
- 69 **Pires LA**, Wagshal AB, Lancey R, Huang SK. Arrhythmias and conduction disturbances after coronary artery bypass graft surgery: epidemiology, management, and prognosis. *Am Heart J* 1995; **129**: 799-808 [PMID: 7900634 DOI: 10.1016/0002-8703(95)90332-1]
- 70 **de Vos CB**, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allessie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. *J Am Coll Cardiol* 2010; **55**: 725-731 [PMID: 20170808 DOI: 10.1016/j.jacc.2009.11.040]
- 71 **Malik S**, Hicks WJ, Schultz L, Penstone P, Gardner J, Katramados AM, Russman AN, Mitsias P, Silver B. Development of a scoring system for atrial fibrillation in acute stroke and transient ischemic attack patients: the LADS scoring system. *J Neurol Sci* 2011; **301**: 27-30 [PMID: 21130468 DOI: 10.1016/j.jns.2010.11.011]
- 72 **Letsas KP**, Efremidis M, Giannopoulos G, Deftereos S, Lioni L, Korantzopoulos P, Vlachos K, Xydonas S, Kossyvakis C, Sideris A. CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation. *Europace* 2014; **16**: 202-207 [PMID: 23813452 DOI: 10.1093/europace/eut210]
- 73 **Bruins P**, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijnsman L, Trouwborst A, Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. *Circulation* 1997; **96**: 3542-3548 [PMID: 9396453 DOI: 10.1161/01.CIR.96.10.3542]
- 74 **Chung MK**, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. *Circulation* 2001; **104**: 2886-2891 [PMID: 11739301 DOI: 10.1161/hc4901.101760]
- 75 **Conway DS**, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. *Am J Cardiol* 2004; **94**:

- 508-510 [PMID: 15325942 DOI: 10.1016/j.amjcard.2004.04.070]
- 76 **Asselbergs FW**, van den Berg MP, Diercks GF, van Gilst WH, van Veldhuisen DJ. C-reactive protein and microalbuminuria are associated with atrial fibrillation. *Int J Cardiol* 2005; **98**: 73-77 [PMID: 15676170 DOI: 10.1016/j.ijcard.2003.12.028]
- 77 **Korantzopoulos P**, Kolettis TM, Kountouris E, Siogas K, Goudevenos JA. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? *Int J Clin Pract* 2005; **59**: 881-885 [PMID: 16033606 DOI: 10.1111/j.1368-5031.2005.00569.x]
- 78 **Gaudino M**, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, Iacoviello L, Donati MB, Schiavello R, Maseri A, Possati G. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? *Circulation* 2003; **108** Suppl 1: II195-II199 [PMID: 12970232 DOI: 10.1161/01.cir.0000087441.48566.0d]
- 79 **Hijazi Z**, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. *Circulation* 2012; **125**: 1605-1616 [PMID: 22374183 DOI: 10.1161/CIRCULATIONAHA.111.038729]
- 80 **Hohnloser SH**, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. *Eur Heart J* 2012; **33**: 2821-2830 [PMID: 22933567 DOI: 10.1093/eurheartj/ehs274]
- 81 **Ellinor PT**, Low AF, Patton KK, Shea MA, Macrae CA. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. *J Am Coll Cardiol* 2005; **45**: 82-86 [PMID: 15629379 DOI: 10.1016/j.jacc.2004.09.045]
- 82 **Jourdain P**, Bellorini M, Funck F, Fulla Y, Guillard N, Loiret J, Thebault B, Sadeg N, Desnos M. Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study. *Eur J Heart Fail* 2002; **4**: 263-267 [PMID: 12034150 DOI: 10.1016/S1388-9842(02)00004-1]
- 83 **Patton KK**, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. *Circulation* 2009; **120**: 1768-1774 [PMID: 19841297 DOI: 10.1161/CIRCULATIONAHA.109.873265]
- 84 **Christersson C**, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. *J Thromb Haemost* 2014; **12**: 1401-1412 [PMID: 24942912 DOI: 10.1111/jth.12638]
- 85 **Okçün B**, Yigit Z, Küçükoglu MS, Mutlu H, Sansoy V, Güzelsoy D, Uner S. Predictors for maintenance of sinus rhythm after cardioversion in patients with nonvalvular atrial fibrillation. *Echocardiography* 2002; **19**: 351-357 [PMID: 12174197 DOI: 10.1046/j.1540-8175.2002.00351.x]
- 86 **Olshansky B**, Heller EN, Mitchell LB, Chandler M, Slater W, Green M, Brodsky M, Barrell P, Greene HL. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. *J Am Coll Cardiol* 2005; **45**: 2026-2033 [PMID: 15963405 DOI: 10.1016/j.jacc.2005.03.020]
- 87 **Li C**, Ding X, Zhang J, Zhou C, Chen Y, Rao L. Does the E/e' index predict the maintenance of sinus rhythm after catheter ablation of atrial fibrillation? *Echocardiography* 2010; **27**: 630-636 [PMID: 20412266 DOI: 10.1111/j.1540-8175.2009.01123]
- 88 **Shaikh AY**, Maan A, Khan UA, Aurigemma GP, Hill JC, Kane JL, Tighe DA, Mick E, McManus DD. Speckle echocardiographic left atrial strain and stiffness index as predictors of maintenance of sinus rhythm after cardioversion for atrial fibrillation: a prospective study. *Cardiovasc Ultrasound* 2012; **10**: 48 [PMID: 23199055 DOI: 10.1186/1476-7120-10-48]
- 89 **Vergara GR**, Marrouche NF. Tailored management of atrial fibrillation using a LGE-MRI based model: from the clinic to the electrophysiology laboratory. *J Cardiovasc Electrophysiol* 2011; **22**: 481-487 [PMID: 21044212 DOI: 10.1111/j.1540-8167.2010.01941]
- 90 **Marrouche NF**, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M, Mahnkopf C, Herweg B, Daoud E, Wissner E, Bansmann P, Brachmann J. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *JAMA* 2014; **311**: 498-506 [PMID: 24496537 DOI: 10.1001/jama.2014.3]
- 91 **Jadidi AS**, Cochet H, Shah AJ, Kim SJ, Duncan E, Miyazaki S, Sermesant M, Lehrmann H, Lederlin M, Linton N, Forclaz A, Nault I, Rivard L, Wright M, Liu X, Scherr D, Wilton SB, Roten L, Pascale P, Derval N, Sacher F, Knecht S, Keyl C, Hocini M, Montaudon M, Laurent F, Haïssaguerre M, Jaïs P. Inverse relationship between fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: combined magnetic resonance imaging and high-density mapping. *J Am Coll Cardiol* 2013; **62**: 802-812 [PMID: 23727084 DOI: 10.1016/j.jacc.2013.03.081]
- 92 **Spragg DD**, Khurram I, Zimmerman SL, Yarmohammadi H, Barcelon B, Needleman M, Edwards D, Marine JE, Calkins H, Nazarian S. Initial experience with magnetic resonance imaging of atrial scar and co-registration with electroanatomic voltage mapping during atrial fibrillation: success and limitations. *Heart Rhythm* 2012; **9**: 2003-2009 [PMID: 23000671 DOI: 10.1016/j.hrthm.2012.08.039]
- 93 **Kottkamp H**. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. *Eur Heart J* 2013; **34**: 2731-2738 [PMID: 23761394 DOI: 10.1093/eurheartj/ehs194]
- 94 **Burstein B**, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. *J Am Coll Cardiol* 2008; **51**: 802-809 [PMID: 18294563 DOI: 10.1016/j.jacc.2007.09.064]
- 95 **Stiles MK**, John B, Wong CX, Kuklik P, Brooks AG, Lau DH, Dimitri H, Roberts-Thomson KC, Wilson L, De Sciscio P, Young GD, Sanders P. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the "second factor". *J Am Coll Cardiol* 2009; **53**: 1182-1191 [PMID: 19341858 DOI: 10.1016/j.jacc.2008.11.054]
- 96 **Lee KW**, Everett TH, Rahmutula D, Guerra JM, Wilson E, Ding C, Olgin JE. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. *Circulation* 2006; **114**: 1703-1712 [PMID: 17030685 DOI: 10.1161/CIRCULATIONAHA.106.624320]
- 97 **Rahmutula D**, Marcus GM, Wilson EE, Ding CH, Xiao Y, Paquet AC, Barbeau R, Barczak AJ, Erle DJ, Olgin JE. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor- β 1. *Cardiovasc Res* 2013; **99**: 769-779 [PMID: 23612580 DOI: 10.1093/cvr/cvt074]

P- Reviewer: Amiya E, Lee TS S- Editor: Gong ZM
L- Editor: A E- Editor: Li D





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

